StockGlow

argenx SE (ARGX)

Develops antibody drugs that reduce immune system attacks on muscles and blood cells.

$872.23-0.02%Healthcare
Compare ARGX with
StockGlow Score
85
Bullish
BearishBullish
1 year ago+29.4%

The outlook

ARGX is trading at $872.23 with analyst consensus solidly on the "Buy" side, and the stock sits well above both its 50- and 200-day moving averages. The average analyst price target sits roughly 24% above the current price, and the stock is positioned about 78% of the way between its 52-week low and high.

What’s behind the score

Analyst consensusBuy — 1.6 avg of 23 analysts
Price trendAbove its 50- & 200-day averages
52-week range78% of the way from its 52-week low to high
Price targetAvg target +24% vs current price

Analyst price target

~12-month · 23 analysts
$1,081.96average target+24.0% vs now
Now $872.23
Low $770.00High $1,350.00

Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.

Market cap
$54.24B
52-wk high
$953.58
52-wk low
$590.78
50-day avg
$866.00
200-day avg
$828.64
Trailing P/E
33.3

Similar stocks

ASNDAscendis Pharma A/S$254.44+0.40%KRYSKrystal Biotech, Inc.$364.23+3.53%GMABGenmab A/S$29.00+0.69%ALNYAlnylam Pharmaceuticals, Inc.$288.41+3.60%LKFTLakefront Biotherapeutics NV$28.15+0.07%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy